162 related articles for article (PubMed ID: 19384691)
1. Selecting promising treatments in randomized Phase II cancer trials with an active control.
Cheung YK
J Biopharm Stat; 2009; 19(3):494-508. PubMed ID: 19384691
[TBL] [Abstract][Full Text] [Related]
2. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
3. Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
Stewart DJ
J Natl Cancer Inst; 2008 Mar; 100(6):445-6; author reply 446. PubMed ID: 18334712
[No Abstract] [Full Text] [Related]
4. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Gridelli C; Morgillo F; Favaretto A; de Marinis F; Chella A; Cerea G; Mattioli R; Tortora G; Rossi A; Fasano M; Pasello G; Ricciardi S; Maione P; Di Maio M; Ciardiello F
Ann Oncol; 2011 Jul; 22(7):1528-1534. PubMed ID: 21212155
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
[TBL] [Abstract][Full Text] [Related]
6. Resampling phase III data to assess phase II trial designs and endpoints.
Sharma MR; Karrison TG; Jin Y; Bies RR; Maitland ML; Stadler WM; Ratain MJ
Clin Cancer Res; 2012 Apr; 18(8):2309-15. PubMed ID: 22287601
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Gridelli C; Rossi A; Mongillo F; Bareschino M; Maione P; Ciardiello F
Clin Lung Cancer; 2007 May; 8(6):396-8. PubMed ID: 17562243
[TBL] [Abstract][Full Text] [Related]
8. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
[TBL] [Abstract][Full Text] [Related]
9. Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Hanna N
J Thorac Oncol; 2006 Nov; 1(9):927-8. PubMed ID: 17409973
[No Abstract] [Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Multiple Histology Phase II Trials.
Leblanc M; Rankin C; Crowley J
Clin Cancer Res; 2009 Jul; 15(13):4256-62. PubMed ID: 19549777
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
14. Choosing phase II endpoints and designs: evaluating the possibilities.
LeBlanc M; Tangen C
Clin Cancer Res; 2012 Apr; 18(8):2130-2. PubMed ID: 22407830
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Lind JS; Meijerink MR; Dingemans AM; van Kuijk C; Ollers MC; de Ruysscher D; Postmus PE; Smit EF
Eur Radiol; 2010 Dec; 20(12):2890-8. PubMed ID: 20625738
[TBL] [Abstract][Full Text] [Related]
16. Between-arm comparisons in randomized Phase II trials.
Jung SH; George SL
J Biopharm Stat; 2009; 19(3):456-68. PubMed ID: 19384688
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the systemic treatment of metastatic papillary renal cancer.
Chowdhury S; Choueiri TK
Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
[TBL] [Abstract][Full Text] [Related]
18. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
Neven A; Mauer M; Hasan B; Sylvester R; Collette L
J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Oberstein PE; Saif MW
JOP; 2011 Mar; 12(2):96-100. PubMed ID: 21386629
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
